National Corporate Housing Releases Annual Corporate Social Responsibility Report Celebrating 25 Years Of Positive Impact
2025 National Corporate Housing Leadership and Sales Conference
GREENWOOD VILLAGE, Colo., June 11, 2025 (GLOBE NEWSWIRE) -- National Corporate Housing has released its annual Corporate Social Responsibility Report that showcases the company's commitment to focusing on people, operating sustainably, and enriching community.
'Corporate social responsibility has been a core part of our mission since Day One, and we are more committed than ever to sustainable growth,' says Tom Atchison, National Corporate Housing CEO and founder. 'Our environmental, social, and governance (ESG) strategy will remain at the heart of our decision-making as we embrace innovation, sustainability, and inclusivity. We are not just preparing for the next 25 years - we are actively shaping them.'
That momentum—and National's principle to always do the right thing— drives progress in every business area. As a global leader in customized corporate housing since 1999, National is proud of the gains it's made in:
Prioritizing peopleNational champions a diverse, inclusive workplace through initiatives that include a DEI Advisory Council, employee resource groups, and a commitment to pay equity and advancement. Ongoing learning opportunities, tuition reimbursement and well-being benefits create a culture of care and support that helps employees thrive.
Increasing sustainability National strives to reduce its carbon footprint and promote sustainable practices. Waste reduction and resource circularity—from buying high-quality durable goods that reduce environmental impact to donating gently used household goods to local nonprofits—helps protect the environment. National also prioritizes partnerships with vendors who are good environmental stewards. In 2026, National will launch an Environmental Awareness Training program for employees to support sustainability goals.
National recently helped launch a tool to measure and manage greenhouse gas emissions from energy use in furnished apartments. This free tool is available to all corporate housing providers to boost the industry's environmental stewardship.
Community Enrichment From the Angel Tree Holiday Drive that provided gifts for children and families in need to the Haven For Hope partnership that provided hygiene essentials for people experiencing homeless, National actively does good for their communities. Paid volunteer leave for employees, Community Impact Awards that fund employee-chosen nonprofits, and ongoing outreach highlight National's commitment to give back.
'The next 25 years will challenge us to think bigger and act bolder,' says Amber Smith, Head of ESG. 'From climate change and digital transformation to evolving definitions of work and belonging, the future will demand innovation, agility, and an unwavering sense of purpose. Here's to the next 25 years of impact, innovation, and inclusion.'
For media inquiries, please contact:Peggy Smith, Chief Innovation Officer, Marketing(720) 392-3990 | psmith@nationalcorporatehousing.com
About National Corporate Housing: At National, we turn complex temporary housing challenges into seamless solutions. As a global leader in customized corporate housing since 1999, we provide personalized, 360-degree services that ensure your employees feel at home, wherever they are in the world. With our extensive network and local expertise, we make the unfamiliar comfortable, delivering exceptional experiences that transform clients into lifelong partners.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a8717bbd-9df8-4afe-bc2a-eaaba3cc2622
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025
Seven months after the completion of dosing: 41% of patients (150 mg Q4W) continue to experience complete response (UAS7=0) 48% of patients (150 mg Q4W) report that CSU no longer impacts their quality of life (DLQI=0/1) KIT related tolerability events demonstrated to be reversible Enrollment to Phase 3 CSU trials ongoing Company to host webcast today at 6:00 pm ET HAMPTON, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today new data demonstrating profound, sustained complete response and improved quality of life at 76 weeks, 7 months after the completion of dosing with barzolvolimab in chronic spontaneous urticaria (CSU), an immune-related condition driven by mast cell activation. Barzolvolimab specifically targets mast cells by binding the receptor tyrosine kinase KIT with high specificity and potently inhibiting its activity, which is required for mast cell function and survival. The data are being presented in a late breaking oral presentation (#100227) at the EAACI Congress 2025. The Company previously announced that this Phase 2 study of barzolvolimab in patients with moderate to severe CSU refractory to antihistamines, including patients with biologic-refractory disease, met its primary endpoint—a significant improvement in UAS7 compared to placebo at 12 weeks—across all dose groups tested. Barzolvolimab also demonstrated rapid, profound complete response rates (UAS7=0; no itch/no hives) in up to 51% of patients at 12 weeks, which continued to deepen over 52 weeks of active therapy to up to 71% of patients. Seven months after completion of dosing, patients continue to experience profound clinical benefit, with up to 41% of patients reporting a complete response at 76 weeks and 48% of patients reporting that their disease no longer impacts their quality of life. Barzolvolimab demonstrated a well tolerated safety profile throughout the study. 'In this large Phase 2 study, patients on barzolvolimab experienced rapid, profound, durable complete response which correlated with meaningful improvements in quality of life—the goal of treatment for patients and physicians,' said Martin Metz, M.D., Professor, Department of Dermatology and Allergy, Head of Translational Research and Deputy Head of Clinical Trials at Charité – Universitätsmedizin in Berlin and the lead investigator of the study. 'By addressing the root driver of chronic spontaneous urticaria, the mast cell, barzolvolimab provided meaningful clinical benefit to more than 90% of the patients on study, including patients with severe disease refractory to omalizumab, and demonstrated a level of sustained complete response after the completion of active therapy that is unprecedented in CSU. Importantly, across this large, 76 week Phase 2 trial, barzolvolimab also presented a favorable safety profile, further supporting barzolvolimab's significant potential to become a transformative treatment option for patients suffering from this often very severe and debilitating disease.' Data highlights at 76 weeks (7 months/28 weeks after completion of barzolvolimab treatment) Rapid, profound improvements in UAS7 (weekly urticaria activity score) were reported as early as one week after dosing. Barzolvolimab achieved the primary efficacy endpoint, a statistically significant mean change from baseline to Week 12 in UAS7 (weekly urticaria activity score) compared to placebo, at all dose levels. These improvements were sustained or deepened at Week 52 and continued to Week 76. UAS7 mean change from baseline at Week 76 was -20.42 for patients treated with 150 mg Q4W and -21.10 for patients treated with 300 mg Q8W. 41% of patients treated with barzolvolimab 150 mg Q4W and 35% of patients treated with 300 mg Q8W had a complete response (no itch/hives; UAS7=0) at Week 76. 56% of patients treated with barzolvolimab 150 mg Q4W and 47% of patients treated with 300 mg Q8W had well controlled disease (UAS7≤6) at Week 76. 48% of patients treated with barzolvolimab 150 mg Q4W and 40% of patients treated with 300 mg Q8W reported that CSU had no impact on their quality of life at 76 weeks as measured by the Dermatology Life Quality Index (DLQI). Current clinical guidelines recommend complete response (UAS7=0) as the goal of treatment1 and achieving complete response is directly correlated to the greatest improvements in quality of life for patients2. These robust responses and improvements in quality of life were observed regardless of prior omalizumab experience. Barzolvolimab was well tolerated with a favorable safety profile through 76 weeks. The most common adverse events were grade 1 (mild), mechanism related (KIT) and reversible. No new safety signals were identified during the follow-up period. As previously disclosed, neutropenia events resolved rapidly and while still receiving barzolvolimab treatment and there was no association between neutropenia and infections. As expected, neutrophil counts returned to baseline following the completion of barzolvolimab treatment and the mild hair color changes and skin hypopigmentation observed on study were demonstrated to be reversible following discontinuation of treatment. 'At every analysis across multiple endpoints in this Phase 2 study, barzolvolimab has demonstrated best in disease data, suggesting barzolvolimab holds great promise as a transformational treatment for patients suffering from CSU— a disease of misery that often impacts all aspects of patients' lives,' said Diane C. Young, M.D., Senior Vice President and Chief Medical Officer of Celldex. 'On behalf of Celldex, I want to thank the patients and physicians who participated in this study. We remain diligently focused on executing across our clinical trials to bring this potential important new medicine to patients.' Results presented at the EAACI Congress 2025 are available on the "Publications' page of the "Science" section of the Celldex website. 1Zuberbier T, et al. Allergy, 2022; 2Kolkhir P, et al. JACI, 2023 Webcast The Company will host a conference call/webcast today to discuss the results at 6:00 pm ET. To access the live and archived webcast, please visit the Events section on the Investor Relations page of Celldex's website. Parties interested in participating via telephone may register here to receive the dial-in numbers and unique PIN to seamlessly access the call. Otherwise please access the listen-only webcast link. The archived webcast will be available for a limited time on the Company's website. About BarzolvolimabBarzolvolimab is a humanized monoclonal antibody that binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity. KIT is expressed in a variety of cells, including mast cells, which mediate inflammatory responses such as hypersensitivity and allergic reactions. KIT signaling controls the differentiation, tissue recruitment, survival and activity of mast cells. In certain inflammatory diseases, such as chronic urticaria, mast cell activation plays a central role in the onset and progression of the disease. Barzolvolimab is currently being studied in chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), prurigo nodularis (PN), eosinophilic esophagitis (EOE) and atopic dermatitis (AD), with additional indications planned for the future. About the Phase 2 CSU StudyThe randomized, double-blind, placebo-controlled, parallel group Phase 2 study evaluated the efficacy and safety profile of multiple dose regimens of barzolvolimab in patients with CSU who remain symptomatic despite antihistamine therapy, to determine the optimal dosing strategy. 208 patients were randomly assigned on a 1:1:1:1 ratio to receive subcutaneous injections of barzolvolimab at 75 mg every 4 weeks, 150 mg every 4 weeks, 300 mg every 8 weeks or placebo during a 16-week placebo-controlled treatment period. After 16 weeks, patients then entered a 36-week active treatment period, in which patients receiving placebo or the 75 mg dose were randomized to receive barzolvolimab 150 mg every 4 weeks or 300 mg every 8 weeks; patients already randomized to the 150 mg and 300 mg treatment arms remained on the same regimen as during the placebo-controlled treatment period. After 52 weeks, patients enter a follow-up period for an additional 24 weeks. Barzolvolimab achieved the primary efficacy endpoint of the study—a statistically significant mean change from baseline to week 12 in UAS7 (weekly urticaria activity score) compared to placebo at all dose levels. For additional information on this trial (NCT05368285), please visit About the Phase 3 ProgramCelldex is currently conducting a global Phase 3 Program for barzolvolimab in CSU, consisting of two Phase 3 trials (EMBARQ-CSU1; NCT06445023 and EMBARQ-CSU2; NCT06455202) designed to establish the efficacy and safety of barzolvolimab in adult patients with CSU who remain symptomatic despite H1 antihistamine treatment. The studies also include patients who remain symptomatic after treatment with biologics. Enrollment is underway. About Chronic Spontaneous Urticaria (CSU)CSU is characterized by the occurrence of hives or wheals for 6 weeks or longer without identifiable specific triggers or causes. The activation of the mast cells in the skin (release of histamines, leukotrienes, chemokines) results in episodes of itchy hives, swelling and inflammation of the skin that can go on for years or even decades. Current therapies provide symptomatic relief only in some patients. About Celldex Celldex is pioneering new horizons in immunology to deliver life-changing therapies. We are relentless in our pursuit of novel antibody-based treatments that engage the human immune system and directly affect critical pathways to improve the lives of patients with allergic, inflammatory and autoimmune Forward Looking StatementThis release contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to successfully complete research and further development and commercialization of Company drug candidates, including barzolvolimab (also referred to as CDX-0159), in current or future indications; the uncertainties inherent in clinical testing and accruing patients for clinical trials; our limited experience in bringing programs through Phase 3 clinical trials; our ability to manage and successfully complete multiple clinical trials and the research and development efforts for our multiple products at varying stages of development; the availability, cost, delivery and quality of clinical materials produced by our own manufacturing facility or supplied by contract manufacturers, who may be our sole source of supply; the timing, cost and uncertainty of obtaining regulatory approvals; the failure of the market for the Company's programs to continue to develop; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; our ability to continue to obtain capital to meet our long-term liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials that we have initiated or plan to initiate; and other factors listed under "Risk Factors" in our annual report on Form 10-K and quarterly reports on Form 10-Q. All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise. Company ContactSarah CavanaughSenior Vice President, Corporate Affairs & Administration(508) 864-8337scavanaugh@ Patrick TillMeru Advisors(484) 788-8560ptill@
Yahoo
2 hours ago
- Yahoo
Meydan Free Zone Leads Compliance Innovation with Smooth Digital Setup Model
Meydan Free Zone launches a fully digital compliance system aligned with UAE and global standards, offering fast approvals, real-time tracking, and risk-based profiling to help entrepreneurs stay audit-ready, meet regulatory demands, and grow efficiently in one of the world's most scrutinized business Courtesy of Meydan Free Zone DUBAI, United Arab Emirates, June 12, 2025 (GLOBE NEWSWIRE) -- In a city recognized for e-government innovation, Meydan Free Zone is setting a new benchmark for digital business formation, unveiling a fully online setup experience that puts trust and transparency at the core of every step. Responding to the rising demand for regulatory accuracy, speed, and clarity, Meydan Free Zone has engineered a five-step, technology-enabled setup process. The system eliminates delays and errors, equipping founders with the tools and confidence needed to scale in one of the world's fastest-moving markets. 'Founders don't just want to move fast—they want to be trusted by banks, regulators, and partners from day one,' said Mohammad Bin Humaidan Al Falasi, Director of Free Zone Licensing at Meydan Free Zone. 'Our platform delivers that trust through technology, automation, and compliance built into every step.' A Fully Digital, Error-Free Setup Journey The Meydan Free Zone experience begins with guided business activity selection, ensuring each company aligns with UAE licensing and banking standards. Entrepreneurs receive legal structure and naming support, and built-in screening protocols prevent delays caused by inconsistencies or regulatory red flags. All submitted documents are subjected to compliance-grade checks, with digital workflows verifying the source of wealth, shareholder structures, and KYC data in accordance with FATF and UAE regulations. Once approvals are secured, trade licenses can be issued in as little as 60 minutes. A key advantage is Meydan's support for corporate bank account opening—a common challenge for new businesses. The platform provides banks with World Check screenings, verified KYC data, and clear shareholder structures, ensuring high approval rates and minimizing delays due to missing or misaligned information. Technology-Driven Transparency and Regulatory Alignment Meydan Free Zone integrates directly with Dubai's Live Compliance Dashboard, enabling real-time document validation and regulatory tracking. The entire setup process is remote, using e-signatures, AI chat assistance, and a blockchain-secured portal to provide full transparency and data integrity. The platform's enhanced compliance engine, launched earlier this year, automates source-of-funds verification, risk profiling, and ongoing due diligence, all aligned with UAE Federal Law and FATF standards. This ensures every business is prepared to meet the city's rigorous regulatory expectations from day one. Recognized as a qualified free zone under the UAE corporate tax framework, Meydan Free Zone offers eligible businesses 0% corporate tax on qualifying income, with registration and filing requirements smoothly integrated into the setup journey. With over 33,000 regulatory inspections conducted in Q1 2023 across the UAE, staying compliant from inception is essential. Meydan's structured digital workflow eliminates setup errors, streamlines government approvals, and ensures that all regulatory documents are aligned with bank and partner requirements, providing entrepreneurs with a clear, easy path from concept to operational launch. Setting the Gold Standard for Modern Business Formation Meydan Free Zone's dedication to a simple, secure, and fully digital setup positions it as a cornerstone of Dubai's future-forward business environment. The platform features UAE Pass connection, ISO-certified data protection, guaranteed bank account access, and real-time regulatory alignment.. About Meydan Free Zone Meydan Free Zone is one of Dubai's most future-focused business hubs. It offers a fully digital setup experience, comprehensive compliance support, and access to over 2,500 business activities. Built for speed, transparency, and simplicity, Meydan empowers entrepreneurs to scale confidently from Dubai to the world. Contact Information: Contact Person's Name: Anisha SagarOrganization / Company: Meydan Free ZoneCompany website: Email Address: anisha@ A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Encore Data Products Attending and Exhibiting at ISTE 2025: Showcasing Next-Gen Educational Tech
Lafayette, June 12, 2025 (GLOBE NEWSWIRE) -- Lafayette, Colorado - Encore Data Products is set to showcase its latest educational technology at the ISTE 2025 conference, happening from June 29 to July 2 in San Antonio. This event is a chance for Encore Data Products to connect with educators and industry experts, showing their dedication to improving learning experiences through cutting-edge tech solutions. One of the most exciting announcements this year is Encore Data Products' expansion into the Translation and Interpretation category with the introduction of IRIS Pen scanners, a powerful tool that helps break language barriers in the classroom and supports diverse learning needs. These smart pens instantly scan and translate printed text into multiple languages, making them ideal for multilingual students, ESL learners, and educators alike. The company is well-known for its wide range of products that serve schools, libraries, and businesses. They offer high-quality headphones, AV technology, and clean & healthy supplies, emphasizing their mission to provide dependable and innovative educational tools. At the conference, visitors will be able to check out their interactive learning tools, such as headphones with microphones and document cameras. They will also introduce some new portable and protective gear. A representative from Encore Data Products, shared her excitement by saying, "The ISTE conference is a fantastic platform for us to connect with educators and tech enthusiasts, demonstrating how our solutions can transform learning environments." She expressed their eagerness to interact with educators from all over and show how their customizable solutions can help make education more interactive and inclusive. The ISTE 2025 conference will feature many exhibitors, and Encore Data Products plans to use this opportunity to highlight their advanced AV technology. They will showcase products like charge & sync solutions and touch-enabled displays, focusing on how versatile and durable their technology is for classrooms. This is part of their strategy to smoothly incorporate digital tools into educational programs, offering practical and efficient resources to teachers and students. To explore the complete range of AV technology offered by Encore Data Products, including charge & sync solutions, visit the AV technology section on their website. A key aspect of Encore Data Products' display will be their emphasis on clean and healthy supplies. Recognizing the importance of hygiene, especially after global health challenges, the company offers solutions like electronic sanitizers and disposable headphone covers for safe shared spaces. These offerings are a response to modern educational needs, ensuring technology doesn't compromise the health of students and staff. Moreover, Encore Data Products will present their STEAM and STEM products, which are meant to support hands-on learning in science, technology, engineering, arts, and mathematics. Their products are designed to encourage teamwork and creative problem-solving. "Participating in ISTE allows us to align our innovations with the current trends and needs identified by educators," added a representative. "Our dedication to supporting educational environments through tailored solutions continues to drive our exploration of new technologies and practices." Encore Data Products is committed to promoting educational excellence, using this conference as a platform to showcase their current products such as the scanner and reading pen, and also learn from educators. This engagement helps shape future product development, reinforcing their reputation as a reliable partner in educational technology. For detailed information about their wide range of headphones and AV accessories, visit the headphones and AV accessories sections on their website. Their presence at ISTE 2025 is intended to deepen conversations about education technology's role in today's classrooms. Attendees looking to explore effective educational tools and gain insights into future-ready learning environments will find value in Encore Data Products' exhibit. The ISTE conference is known for bringing together educators and tech leaders to discuss the future of educational technology. By attending this year, Encore Data Products aims to contribute meaningfully to these discussions with practical solutions that meet the ever-changing needs of educators. The company's exhibit will be open throughout the conference from June 29 to July 2, offering hands-on demonstrations and expert consultations for all attendees. Recent News: Encore Data Products Unveils Califone Soft Floor Rockers and Gaming Chairs for Ultimate Comfort and Support ### For more information about Encore Data Products, contact the company here:Encore Data ProductsMedia Relations866-926-1669marketing@ Majestic Drive, Suite 5Lafayette, Colorado 80026 CONTACT: Media RelationsSign in to access your portfolio
